PT Inquest is an online journal club. Hosted by Erik Meira and JW Matheson, the show looks at an article every week and discusses how they apply to current physical therapy practice.
John B. Buse, MD, PhD - Complex Cases in Contemporary Practice: Applying New Evidence for SGLT2 Inhibitors in the Management of Patients With Comorbid Cardiometabolic Diseases
Manage episode 272423639 series 103449
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.